DGAP-News: First surgeries performed as part of human clinical study for antibacterial silver coating technology; aap's technology effective against particularly critical antibiotic-resistant hospital germ MRSA
DGAP-News: aap Implantate AG
/ Key word(s): Study
First surgeries performed as part of human clinical study for antibacterial silver coating technology; aap's technology effective against particularly critical antibiotic-resistant hospital germ MRSA
06.04.2022 / 11:36
The issuer is solely responsible for the content of this announcement.
aap Implantate AG ("aap" or the "Company") announces that in the first quarter of 2022 the first surgeries were performed as part of the human clinical trial for its innovative antibacterial silver coating technology. The surgeries took place at the University Hospital Regensburg and went according to plan. aap had initiated the human clinical trial in December last year, which is an essential step towards the planned market approval (CE) of the innovative technology.
In addition, aap reports that its antibacterial silver coating technology is effective against the particularly critical antibiotic-resistant hospital germ methicillin-resistant Staphylococcus aureus (MRSA), which was responsible for 100,000 deaths worldwide in 2019 alone, according to a study published in the medical journal The Lancet. Last year, for example, aap was able to demonstrate the effectiveness of its technology against the antibiotic-resistant bacterium MRSA as part of an extensive series of in vitro tests. MRSA is one of the pathogens most frequently responsible for resistance problems. The results of the study on the threat posed by antibiotic-resistant germs, which was written by an international group of experts, were published in the scientific journal "The Lancet". In addition, n-tv had also recently evaluated the results of the study. According to the study, more than 1.2 million people worldwide died directly from an infection with an antibiotic-resistant pathogen in 2019. In addition, such infections were at least partly responsible for almost five million further deaths. This makes antibiotic resistance one of the leading causes of death in the world. The results of the study reveal the extent of the problem caused by multi-resistant germs and at the same time show the acute need for action. This is precisely the starting point for aap's innovative antibacterial silver coating technology. The disruptive silver coating developed by the company represents an alternative solution in the fight against bacterial infections that is not based on antibiotics and therefore offers enormous market potential. As a platform technology, the technology has a broad range of applications and can be used not only in traumatology but also in other areas of orthopedics as well as in cardiology, dentistry or medical instruments.
Finally, in connection with the information contained in this press release, we may also refer to an interview with Prof. Dr. Dr. Volker Alt, Director of the Clinic for Trauma Surgery at the University Hospital Regensburg and an expert in the field of antimicrobial coatings, in which he talks about implant-related infections in connection with antibiotic resistance and also makes a clear case for the need for antibacterial coatings on implants that are not based on antibiotics (https://www.youtube.com/watch?v=q1UluZIkrMo).
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German Stock Exchanges -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company headquartered in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ(R), the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. This involves sales both via distribution agents and as part of partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.
This release may contain forward-looking statements based on current expectations, beliefs and projections of the Management Board and currently available information. The forward-looking statements are not guarantees of future performance or results. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. We assume no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.
 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis; Antimicrobial Resistance Collaborators; Published: January 19, 2022; DOI: https://doi.org/10.1016/S0140-6736(21)02724-0
 log4 reduction after three days of pre-incubation (in vitro) and log3 reduction after seven days of pre-incubation (in vitro).
aap Implantate AG; Marek Hahn; Member of the Management Board/ CFO; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290;[email protected]
06.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
||aap Implantate AG
||+49 (0) 30 75 01 90
||+49 (0) 30 75 01 91 11
||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
|EQS News ID:
|End of News
||DGAP News Service
Quelle: boersengefluester.de und Firmenangaben
Die wichtigsten Finanzdaten auf einen Blick
|Ergebnis je Aktie8
Geschäftsbericht 2021 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
||Kurs in €
||Börsenwert in Mio. €
|Dividende '20 in €
||Dividende '21e in €
||Performance 52 Wochen